GlassScriptPhysician profile
Marcy R Workman
NPI 1891751426
$15,035.69
in general payments reported to CMS, 2019-2025
27 companies · $3,465 in 2025
The $3,465 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,843 · 2022: $3,137 · 2023: $3,283 · 2024: $3,309 · 2025: $3,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,337 · Education: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,337.48 |
| Education | $719.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,926.95 | 2021-2025 | |
| Janssen Biotech, INC. | $1,853.25 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $1,285.38 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Amgen INC. | $1,074.70 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $1,060.95 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $1,001.06 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $897.75 | 2021-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $784.01 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $661.57 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $583.01 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $574.58 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $482.71 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $320.36 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $220.22 | 2021-2024 | Jublia |
| Dermavant Sciences, INC. | $216.87 | 2022-2024 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.55 | 2022-2025 | Spevigo |
| Incyte Corporation | $193.84 | 2022-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $182.24 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Sanofi-Aventis U.S. LLC | $154.99 | 2022-2024 | |
| Almirall LLC | $133.99 | 2021-2025 | Seysara |
| Journey Medical Corporation | $74.16 | 2022 | |
| Genentech USA, INC. | $33.28 | 2022-2023 | Xolair |
| Epi Health, LLC | $32.05 | 2022 | |
| Kyowa Kirin, INC. | $28.46 | 2022-2023 | Poteligeo |
| Convatec INC. | $21.39 | 2025 | |
| Dermira, INC. | $19.04 | 2021 | |
| Biofrontera INC. | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcy Workman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.